Recommended Prophylactic Anticoagulant Dosing

Standard Dosing Regimens

The American College of Cardiology recommends enoxaparin 40 mg subcutaneously once daily or unfractionated heparin (UFH) 5000 units subcutaneously every 8 hours for VTE prophylaxis in hospitalized patients, with the choice depending on renal function and patient-specific factors 1, 2
For acutely ill medical patients, non-orthopedic surgical patients, and cancer patients, the standard prophylactic dose is enoxaparin 40 mg subcutaneously once daily throughout hospitalization 1, 3, 4
For orthopedic surgery, enoxaparin 30 mg subcutaneously twice daily starting 12 hours before or after surgery is recommended, continued for 10-14 days with consideration for extension up to 35 days 1, 4
UFH 5000 units subcutaneously every 8 hours is the preferred regimen for cancer patients and high-risk populations, providing a more consistent anticoagulant effect than twice-daily dosing 1, 5, 2, 6
Fondaparinux 2.5 mg subcutaneously once daily is an effective alternative for medical and surgical patients 1
Dalteparin 2500-5000 IU subcutaneously once daily is an alternative, depending on surgical risk 1

For patients with renal impairment (creatinine clearance <30 mL/min), reduce enoxaparin to 30 mg subcutaneously once daily due to reduced drug clearance and increased bleeding risk 1, 7, 4
UFH is preferred in severe renal impairment as it is primarily metabolized hepatically, not renally, and requires no dose adjustment 2, 6
Fondaparinux is contraindicated in severe renal insufficiency 1, 2
For obese patients (BMI >30 kg/m² or weight >100 kg), consider enoxaparin 40 mg subcutaneously every 12 hours or weight-based dosing at 0.5 mg/kg every 12 hours for adequate prophylaxis 2, 4
For UFH, use 5000 units every 8 hours (not every 12 hours) in patients weighing ≥100 kg to maintain therapeutic levels 6

Continue prophylaxis throughout hospitalization for medical patients until fully ambulatory 1, 5, 4
Minimum 7-10 days for surgical patients, with consideration for extended prophylaxis up to 35 days for high-risk orthopedic and cancer surgery patients 1, 2, 4
Extended prophylaxis beyond hospital discharge increases bleeding risk without clear benefit in most medical patients 3

Routine anti-Factor Xa monitoring is not required for prophylactic doses in most patients 4
Monitor platelet counts every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT) 2, 4
For severe renal impairment on prolonged enoxaparin therapy, consider monitoring anti-Xa levels with target 0.2-0.4 IU/mL for prophylaxis 4